Logo image of LIPO

LIPELLA PHARMACEUTICALS INC (LIPO) Stock Fundamental Analysis

NASDAQ:LIPO - Nasdaq - US53630L2097 - Common Stock - Currency: USD

2.88  -0.03 (-1.03%)

After market: 2.88 0 (0%)

Fundamental Rating

3

Taking everything into account, LIPO scores 3 out of 10 in our fundamental rating. LIPO was compared to 559 industry peers in the Biotechnology industry. While LIPO has a great health rating, there are worries on its profitability. LIPO does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year LIPO has reported negative net income.
LIPO had a negative operating cash flow in the past year.
LIPO had negative earnings in each of the past 5 years.
LIPO had a negative operating cash flow in each of the past 5 years.
LIPO Yearly Net Income VS EBIT VS OCF VS FCFLIPO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -1M -2M -3M -4M -5M

1.2 Ratios

The Return On Assets of LIPO (-105.66%) is worse than 78.00% of its industry peers.
With a Return On Equity value of -125.78%, LIPO perfoms like the industry average, outperforming 40.97% of the companies in the same industry.
Industry RankSector Rank
ROA -105.66%
ROE -125.78%
ROIC N/A
ROA(3y)-120.13%
ROA(5y)-91.9%
ROE(3y)-154.59%
ROE(5y)-121.63%
ROIC(3y)N/A
ROIC(5y)N/A
LIPO Yearly ROA, ROE, ROICLIPO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -100 -200

1.3 Margins

LIPO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LIPO Yearly Profit, Operating, Gross MarginsLIPO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -500 -1K

More info and screens

8

2. Health

2.1 Basic Checks

LIPO does not have a ROIC to compare to the WACC, probably because it is not profitable.
LIPO has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, LIPO has less shares outstanding
There is no outstanding debt for LIPO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
LIPO Yearly Shares OutstandingLIPO Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M 5M
LIPO Yearly Total Debt VS Total AssetsLIPO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M 5M

2.2 Solvency

LIPO has an Altman-Z score of 2.72. This is not the best score and indicates that LIPO is in the grey zone with still only limited risk for bankruptcy at the moment.
The Altman-Z score of LIPO (2.72) is better than 72.09% of its industry peers.
There is no outstanding debt for LIPO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.72
ROIC/WACCN/A
WACC9.64%
LIPO Yearly LT Debt VS Equity VS FCFLIPO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 2M -2M 4M

2.3 Liquidity

A Current Ratio of 6.21 indicates that LIPO has no problem at all paying its short term obligations.
With a decent Current ratio value of 6.21, LIPO is doing good in the industry, outperforming 62.08% of the companies in the same industry.
LIPO has a Quick Ratio of 6.21. This indicates that LIPO is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 6.21, LIPO is doing good in the industry, outperforming 62.61% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.21
Quick Ratio 6.21
LIPO Yearly Current Assets VS Current LiabilitesLIPO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M 5M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for LIPO have decreased strongly by -56.74% in the last year.
The Revenue has grown by 8.88% in the past year. This is quite good.
LIPO shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -5.04% yearly.
EPS 1Y (TTM)-56.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%51.42%
Revenue 1Y (TTM)8.88%
Revenue growth 3Y27.4%
Revenue growth 5Y-5.04%
Sales Q2Q%-11.31%

3.2 Future

The Earnings Per Share is expected to grow by 19.87% on average over the next years. This is quite good.
The Revenue is expected to decrease by -41.42% on average over the next years. This is quite bad
EPS Next Y33.76%
EPS Next 2Y-48.97%
EPS Next 3Y19.87%
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
LIPO Yearly Revenue VS EstimatesLIPO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 200K 400K 600K 800K
LIPO Yearly EPS VS EstimatesLIPO Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 -5 -10 -15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

LIPO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year LIPO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LIPO Price Earnings VS Forward Price EarningsLIPO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LIPO Per share dataLIPO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15

4.3 Compensation for Growth

A more expensive valuation may be justified as LIPO's earnings are expected to grow with 19.87% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-48.97%
EPS Next 3Y19.87%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for LIPO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LIPELLA PHARMACEUTICALS INC

NASDAQ:LIPO (6/10/2025, 8:00:02 PM)

After market: 2.88 0 (0%)

2.88

-0.03 (-1.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-28 2025-03-28/bmo
Earnings (Next)N/A N/A
Inst Owners6.1%
Inst Owner Change-78.87%
Ins Owners24.35%
Ins Owner Change0%
Market Cap12.87M
Analysts82.86
Price Target10.2 (254.17%)
Short Float %2.91%
Short Ratio1.39
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 24.76
P/FCF N/A
P/OCF N/A
P/B 3.16
P/tB 3.16
EV/EBITDA N/A
EPS(TTM)-4.1
EYN/A
EPS(NY)-17.77
Fwd EYN/A
FCF(TTM)-0.89
FCFYN/A
OCF(TTM)-0.89
OCFYN/A
SpS0.12
BVpS0.91
TBVpS0.91
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -105.66%
ROE -125.78%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-120.13%
ROA(5y)-91.9%
ROE(3y)-154.59%
ROE(5y)-121.63%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.11
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.21
Quick Ratio 6.21
Altman-Z 2.72
F-Score5
WACC9.64%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-56.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%51.42%
EPS Next Y33.76%
EPS Next 2Y-48.97%
EPS Next 3Y19.87%
EPS Next 5YN/A
Revenue 1Y (TTM)8.88%
Revenue growth 3Y27.4%
Revenue growth 5Y-5.04%
Sales Q2Q%-11.31%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-6.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-24.84%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-25.41%
OCF growth 3YN/A
OCF growth 5YN/A